معرفی
May Elizabeth Sharpe is a Group Leader of the MX Samples group at the Paul Scherrer Institute (PSI), Switzerland. She leads efforts in macromolecular crystallography (MX) sample preparation, protein crystallization facility management, and high-throughput fragment screening. Her roles include overseeing the PSI Crystallisation Facility and the Fast Fragment and Compound Screening pipeline. She holds a B.Sc. (First Class Honours) in Biochemistry from the University of Sussex (2004) and a Ph.D. in Structural Biology from the University of Bristol (2008). Her research focuses on protein crystallization method development, fragment-based drug discovery, and advancing synchrotron/XFEL beamline technologies for structural biology.
Key research contributions include optimizing crystal growth via microseed matrix screening, developing automated workflows for high-throughput crystallography, and analyzing SARS-CoV-2 protease inhibitors using X-ray crystallography. She has pioneered the HEIDI experiment-management system and SDU data collection software, enabling scalable drug screening. Her work bridges structural biology, automation, and translational drug discovery.
Her publications reflect expertise in fragment screening, protein-ligand interactions, and structural analysis of medically relevant proteins. She has collaborated internationally, contributing to cancer drug target studies and antiviral research. No scientific awards are explicitly listed, though her impactful contributions suggest potential recognition in structural biology circles.
May’s advisory and facility management roles ensure PSI remains a global leader in MX infrastructure. Her lab supports academic and industrial users via crystallization robotics and beamline optimization, advancing structural biology applications in drug development and fundamental research.
